Innate Pharma

Hélène Sicard

Renaud Buffet

Carine Paturel

Laurent Gauthier

Benjamin Rossi

Cécile Bonnafous

Mathieu Blery

Christian Belmant

Stéphanie Cornen

Cecile Bonnafous

François Romagne

Jérôme Tiollier

Simon Kollnberger

Stéphanie Zerbib

The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma

The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

Treatment of peripheral T cell lymphoma

This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

Treatment with anti-KIR3DL2 agents

The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

KIR3DL2 binding agents

Growing community of inventors

Marseilles, France

Hélène Sicard